KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Gains from Investment Securities: 2018-2020

Historic Gains from Investment Securities for Esperion Therapeutics (ESPR) over the last 2 years, with Jun 2020 value amounting to $4.6 million.

  • Esperion Therapeutics' Gains from Investment Securities fell 14.00% to $4.6 million in Q2 2020 from the same period last year, while for Jun 2020 it was $4.6 million, marking a year-over-year decrease of 14.00%. This contributed to the annual value of $4.7 million for FY2019, which is 11.80% down from last year.
  • As of Q2 2020, Esperion Therapeutics' Gains from Investment Securities stood at $4.6 million, which was down 5.21% from $4.8 million recorded in Q1 2020.
  • In the past 5 years, Esperion Therapeutics' Gains from Investment Securities ranged from a high of $5.3 million in Q2 2019 and a low of $4.2 million during Q1 2018.
  • Its 3-year average for Gains from Investment Securities is $4.8 million, with a median of $4.8 million in 2019.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first grew by 25.42% in 2019, then decreased by 14.00% in 2020.
  • Over the past 3 years, Esperion Therapeutics' Gains from Investment Securities (Quarterly) stood at $5.3 million in 2018, then dropped by 11.80% to $4.7 million in 2019, then fell by 14.00% to $4.6 million in 2020.
  • Its Gains from Investment Securities was $4.6 million in Q2 2020, compared to $4.8 million in Q1 2020 and $4.7 million in Q4 2019.